scispace - formally typeset
L

Laura A. Carleton

Researcher at National University of Ireland, Galway

Publications -  7
Citations -  5375

Laura A. Carleton is an academic researcher from National University of Ireland, Galway. The author has contributed to research in topics: Autophagy & Programmed cell death. The author has an hindex of 6, co-authored 6 publications receiving 4926 citations.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal Article

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2459 more
- 01 Jan 2016 - 
Journal ArticleDOI

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Daniel J. Klionsky, +2522 more
- 01 Jan 2016 - 
TL;DR: Author(s): Klionsky, DJ; Abdelmohsen, K; Abe, A; Abedin, MJ; Abeliovich, H; A Frozena, AA; Adachi, H, Adeli, K, Adhihetty, PJ; Adler, SG; Agam, G; Agarwal, R; Aghi, MK; Agnello, M; Agostinis, P; Aguilar, PV; Aguirre-Ghis
Journal ArticleDOI

Nerve growth factor-mediated inhibition of apoptosis post-caspase activation is due to removal of active caspase-3 in a lysosome-dependent manner

Katarzyna Mnich, +5 more
- 01 May 2014 - 
TL;DR: An anti-apoptotic mechanism by which NGF induces removal of active caspase-3 in a lysosome-dependent manner is suggested.
Journal ArticleDOI

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance

Aidan P. Toner, +11 more
- 15 Oct 2013 - 
TL;DR: EL102 shows potential as both a single agent and within combination regimens for the treatment of prostate cancer, particularly in the chemoresistance setting, and in vivo, a combination of EL102 and docetaxel exhibits superior tumour inhibition.